Creative Medical Technology Holdings Recruits Internationally Renowned Kidney Expert to Scientific Advisory Board

Rhea-AI Summary

Creative Medical Technology Holdings (OTC-CELZ) has appointed Dr. Caigan Du, an Associate Professor at the University of British Columbia, to its Scientific Advisory Board. Dr. Du is recognized for his research on kidney failure and transplant rejection, and has received funding from key organizations. He expressed enthusiasm about the potential of ImmCelz®, a regenerative therapy utilizing reprogrammed immune cells to aid kidney regeneration. This recruitment aims to enhance the company's scientific leadership in regenerative medicine.

Positive

• Appointment of Dr. Caigan Du to the Scientific Advisory Board enhances scientific expertise in kidney research.
• Dr. Du's research aligns with the company's focus on ImmCelz®, potentially strengthening its position in regenerative medicine.

Negative

• None.

PHOENIX, Feb. 8, 2021 /PRNewswire/ -- (OTC-CELZ) Creative Medical Technology Holdings Inc. announced today recruitment of Dr. Caigan Du, Associate Professor at the University of British Columbia to the Company's Scientific Advisory Board. 

Dr. Du is a top researcher in the area of molecular and immunological understanding of kidney failure and transplant rejection.  Dr. Du is funded by numerous national and international organizations including the Kidney Foundation and the Canadian Institutes of Health Research.

"I am honored to work with Creative Medical Technology Holdings in this fascinating field of leveraging reprogrammed immune cells for regenerating injured kidneys." Said Dr. Du.  "To date people think about regenerative medicine and immunology as separate fields.  It is very exciting to consider the possibility that immune cells can act as a catalyst for regenerative processes: this is the basis of the ImmCelz® product."

ImmCelz® is a personalized cell therapy generated by incubation of patient cells with allogeneic JadiCell stem cells under proprietary conditions.  The JadiCell possess potent ability to reprogram the immune system, as exemplified in part by their ability to significantly extend survival of COVID patients in an FDA double blind, placebo controlled, clinical trial¹.  ImmCelz® has been demonstrated effective in animal models of rheumatoid arthritis², liver failure³, stroke⁴, type 1 diabetes⁵ and kidney failure⁶.  Scientific studies suggest ImmCelz® functions through secretion of a fundamentally important molecule called Hepatocyte Growth Factor⁷, as well as stimulation of T regulatory cells, a type of immune system cell that suppresses pathological immunity⁸.

"As a clinical-stage biotechnology company, having already commercialized other stem cell products, we understand the key to any success is based on the ability to attract scientific key opinion leaders." Said Timothy Warbington, President and CEO of Creative Medical Technology Holdings. "Dr. Du is a visionary and pioneer in understanding of kidney diseases and we wholeheartedly look forward to him joining our scientific advisory board."

The Advisory Board of Creative Medical Technology Holdings includes internationally renowned neurologist Santosh Kesari MD, Ph.D, the former head of cardiology at Cedar Sinai Medical Center Timothy Henry, MD and our Director Dr. Amit Patel, inventor of the JadiCell and the first physician to have implanted stem cells into the human heart.

About Creative Medical Technology Holdings
Creative Medical Technology Holdings, Inc. is a commercial stage biotechnology company specializing in regenerative medicine/stem cell technology in the fields of immunotherapy, urology, neurology and orthopedics and is listed on the OTC under the ticker symbol CELZ. For further information about the company, please visit www.creativemedicaltechnology.com. 

Forward Looking Statements
OTC Markets has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This news release may contain forward-looking statements including but not limited to comments regarding the timing and content of upcoming clinical trials and laboratory results, marketing efforts, funding, etc. Forward-looking statements address future events and conditions and, therefore, involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements. See the periodic and other reports filed by Creative Medical Technology Holdings, Inc. with the Securities and Exchange Commission and available on the Commission's website at www.sec.gov.

Creativemedicaltechnology.com
www.StemSpine.com
www.Caverstem.com
www.Femcelz.com                                                                                                                                    ImmCelz.com

1 Umbilical cord mesenchymal stem cells for COVID–19 acute respiratory distress syndrome: A double–blind, phase 1/2a, randomized controlled trial - Lanzoni - - STEM CELLS Translational Medicine - Wiley Online Library
2 Creative Medical Technology Holdings Reports Positive Preclinical Data on ImmCelz® Immunotherapy Product in Rheumatoid Arthritis Model | BioSpace
3 Creative Medical Technology Holdings Announces Reversion of Liver Failure Using ImmCelz® Personalized Cellular Immunotherapy in Preclinical Model | Nasdaq
4 Creative Medical Technology Holdings Identifies Mechanism of Action of ImmCelz® Stroke Regenerative Activity (prnewswire.com)
5 Creative Medical Technology Holdings Announces Positive Data and Patent Filing Using ImmCelz® to Treat Type 1 Diabetes (prnewswire.com)
6 Creative Medical Technology Holdings Files Patent based on Positive Data on Renal Failure using ImmCelz® Regenerative Immunotherapy (prnewswire.com)
7 Creative Medical Technology Holdings Identifies and Files Patent on Novel Mechanism of ImmCelz® Therapeutic Activity (apnews.com)
8 Creative Medical Technology Holdings Identifies Mechanism of Action of ImmCelz® Stroke Regenerative Activity (prnewswire.com)

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/creative-medical-technology-holdings-recruits-internationally-renowned-kidney-expert-to-scientific-advisory-board-301223686.html

SOURCE Creative Medical Technology Holdings, Inc.

FAQ

Who is Dr. Caigan Du and what is his role at Creative Medical Technology Holdings?

Dr. Caigan Du is an Associate Professor at the University of British Columbia, recently appointed to the Scientific Advisory Board of Creative Medical Technology Holdings, focusing on kidney research.

What is ImmCelz® and how is it related to the recent appointment of Dr. Du?

ImmCelz® is a personalized cell therapy designed to regenerate injured kidneys, and Dr. Du's expertise in kidney diseases will contribute to its development.

What impact might Dr. Du's recruitment have on CELZ's stock performance?

The addition of Dr. Du could enhance the company's scientific credibility, potentially leading to positive investor sentiment around CELZ.

When was Dr. Du appointed to the advisory board of Creative Medical Technology Holdings?

Dr. Caigan Du was announced as a member of the Scientific Advisory Board on February 8, 2021.